All In Biotech

Drug Trial Radar · NCT03440736

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

A Randomized, Multicenter 28 Week Study to Compare the Efficacy and Safety of Combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) With a Lifestyle Intervention to Cosentyx Therapy Alone in Adult Patients With Moderate to Severe Plaque-type Psoriasis and Concomitant Metabolic Syndrome, Followed by a 28 Week Extension Period

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 781 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

781

Actual

Start

Feb 28, 2018

Primary completion

Nov 30, 2021

Study completion Jun 3, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could primarily improve skin symptoms and secondly cardiometabolic status more than Secukinumab alone in psoriasis patients with concomitant metabolic syndrome by targeting the shared pathophysiology behind both diseases, which is systemic inflammation.

Conditions

  • Psoriasis
  • Metabolic Syndrome

Interventions

  • SecukinumabDrug

    Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)

  • Life-style interventionBehavioral

    A structured program to guide weight loss and increased physical activity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Achieving Psoriasis Area and Severity Index (PASI) Score of 90 at Week 28Time frame: Baseline, Week 28

Locations

75 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Andernach, Germany

  • Novartis Investigative Site

    Augsburg, Germany

  • Novartis Investigative Site

    Bad Soden, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bielefeld, Germany

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Braunschweig, Germany

  • Novartis Investigative Site

    Darmstadt, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Düsseldorf, Germany

  • Novartis Investigative Site

    Erlangen, Germany

  • Novartis Investigative Site

    Falkensee, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Friedrichshafen, Germany

  • Novartis Investigative Site

    Gera, Germany

  • Novartis Investigative Site

    Greifswald, Germany

  • Novartis Investigative Site

    Hagen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hanau, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Ibbenbueren, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    Löhne, Germany

  • Novartis Investigative Site

    Lüdenscheid, Germany

  • Novartis Investigative Site

    Magdeburg, Germany

  • Novartis Investigative Site

    Magdeburg, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Memmingen, Germany

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.